Palvella Therapeutics reveals positive Phase 3 SELVA results and upsized $216M financing
Share
Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.
